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Abstract: Neurosarcoidosis is an uncommon but potentially serious manifestation of sarcoidosis. While the cranial nerves 
are most frequently affected, neurosarcoidosis can involve other nervous system tissues including the meninges, brain pa-
renchyma (especially the hypothalamic region), spinal cord, peripheral nerve, and muscle. Diagnosis may be particularly 
challenging when neurosarcoidosis occurs in isolation. Diagnostic criteria usually include histologic identification of a 
noncaseating granuloma, supportive laboratory or imaging tests or both, and a compatible clinical course. Treatment has 
not been subjected to rigorous study, but corticosteroids are typically the first line of therapy and approximately half of 
patients have substantial benefit. For patients who are refractory to or intolerant of corticosteroid therapy, second-line 
agents include azathioprine, methotrexate, cyclosporine, cyclophosphamide, mycophenolate, and even cranial irradiation. 
The combination of infliximab and mycophenolate mofetil is under study as well. Treatment options will likely evolve as 
well-designed studies are undertaken. 
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INTRODUCTION 
  Sarcoidosis is a systemic granulomatous disease that is 
still of undetermined etiology [1, 2]. In the United States, the 
incidence ranges from 11 per 100,000 in Caucasians to 36 
per 100,000 in African-Americans, and it tends to manifest 
prior to age 40. However, it occurs in people of all ages and 
races [1, 2]. The respiratory and lymphatic systems are most 
commonly affected [1]. When the nervous system is   
involved as it is in about 5-13% of cases, that involvement is 
termed “neurosarcoidosis” [3-6]. Neurosarcoidosis can occur 
either in isolation or along with other features of systemic 
sarcoidosis. 
  Neurosarcoidosis has protean manifestations and can 
masquerade as many other diseases. It can affect a combina-
tion of intracranial structures, such as leptomeninges, cranial 
nerves and hypothalamus, and it can affect the spinal   
cord and its coverings as well as peripheral nerve and   
muscle. 
  Spontaneous improvement or remissions occur in about 
60% of patients with neurosarcoidosis [7]. The mortality rate 
in all forms of sarcoidosis is from 1-5% and is due to severe 
pulmonary, cardiac, or neurologic disease [8]. 
  Most of our current knowledge of neurosarcoidosis 
comes from retrospective and autopsy series, and from   
studies involving patients with systemic sarcoidosis. The 
immunopathogenesis and treatments of neurosarcoidosis   
are similar to those of systemic disease, and they have   
not been subjected to placebo-controlled, double-blinded 
studies. 
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EPIDEMIOLOGY OF NEUROSARCOIDOSIS 
  The typical mean age of onset is from 33 to 41 years, 
slightly later compared to other forms of sarcoidosis [4, 9-
11]. About half of these patients have known generalized 
disease, and 30-70% present with neurologic symptoms [4, 
6, 9]. Neurologic manifestations usually occur within the 
first two years of illness [4, 10]. In general, neurosarcoidosis, 
like systemic sarcoidosis, is more common among blacks. 
Women make up the majority in most, but not all, series. For 
example, in the large series reported by Stern, et al., 85% of 
patients with neurosarcoidosis were black, and 64% were 
female [4]. In contrast however, a French study of 35 pa-
tients reported that 91% were Caucasian [6], and a United 
Kingdom study reported that 29 of 30 patients were Cauca-
sian, and 53% were male [9]. 
  Risk factors specific to neurosarcoidosis have not been 
identified. Research involving the immunopathogenic   
aspects of neurosarcoidosis is lacking, and it is currently   
felt that the inflammatory response in the nervous system is 
similar to that seen in other organs, including the lung. The 
immunopathogenesis of sarcoidosis will be discussed later. 
CRANIAL NEUROSARCOIDOSIS 
  Symptoms of cranial neurosarcoidosis are varied and 
commonly include headache, ataxia, visual disturbances, 
fatigue, nausea and vomiting. Others include weakness, sen-
sory disturbances, seizures, cognitive dysfunction, eye pain, 
depression, aphasia, and tremor [9]. The combination of 
symptoms present in an individual depends on the localiza-
tion of the inflammatory process. 
Cranial Neuropathies 
  Cranial neuropathies are the most common manifestation 
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nial nerve (CN) may be affected, and multiple cranial nerve 
involvement is common. In older series, the most frequently 
affected CN is VII, and sometimes bilateral facial neuropa-
thies are present [10]. In the more recent series, optic neu-
ropathy (discussed below) is more common [9]. Involvement 
of CN VIII (uni- or bilaterally) can cause auditory or vesti-
bular dysfunction [4], but it may be asymptomatic and   
detected by brainstem auditory-evoked responses [10]. 
Nerves involved in eye movement (CN III, IV, and VI)   
may also be affected. Olfactory involvement is somewhat   
uncommon and causes anosmia and impaired taste [10, 13]. 
  Cranial neuropathies may occur because of basilar men-
ingitis, but infiltration or compression of nerves along their 
course can cause their dysfunction. For example, olfactory 
nerve dysfunction can occur from olfactory bulb involve-
ment as well as from involvement of the nasal mucosa [13]. 
In the latter instance, it can be diagnosed by nasal biopsy. In 
addition, some facial neuropathies probably occur from basi-
lar meningitis, while other cases may be due to granuloma-
tous involvement of the extracranial portion of the nerve. 
Optic Neuropathy 
  Optic neuropathy is uncommon in some series but more 
common in others (Table 1), and it may be serious. Bilateral 
involvement sometimes occurs [11]. Symptoms and signs 
may include decreased or blurred vision, papilledema, optic 
nerve atrophy, retrobulbar pain, visual field defects, and pu-
pillary abnormalities [5, 11]. There may be local granuloma-
tous involvement of the optic nerve, but papilledema can 
also be caused by increased intracranial pressure from hy-
drocephalus or meningeal involvement. Overall, optic neu-
ropathy is less frequent than other common ocular features of 
sarcoidosis including anterior uveitis, conjunctival granulo-
mas, scleritis, episcleritis, keratitis, posterior segment disor-
ders, and lacrimal involvement with sicca symptoms [14]. 
Acute or Chronic Meningitis 
  Meningeal infiltration preferentially involves the basal 
leptomeninges. It has been reported in up to 40% of patients 
(Table 1). It may manifest with cranial nerve palsies. It can 
lead to hydrocephalous from cerebrospinal fluid outflow 
obstruction, ventricular system granulomas, or choroid 
plexus infiltration [5]. Cerebrospinal fluid (CSF) studies --
discussed in detail later-- reveal mononuclear inflammatory 
cells with an elevated protein. Occasionally, the glucose is 
low. Magnetic resonance imaging (MRI) with contrast usu-
ally reveals leptomeningeal enhancement. The course can be 
monophasic, chronic, or relapsing, and is usually associated 
with a good outcome [8]. 
Hypothalamic Dysfunction, Intracranial Masses, and 
Encephalopathy 
  Hypothalamic and pituitary dysfunction are relatively 
common (Table 1), usually due to subependymal granuloma-
tous infiltration in the region of the third ventricle. Diabetes 
insipidus and hyperprolactinemia are the two most common 
endocrine manifestations along with hypogonadism [15]. 
  Encephalopathy can occur from neuroendocrine distur-
bances, leptomeningeal infiltration, mass lesions, seizures, 
and small vessel vasculitis. Rarely, central nervous system 
(CNS) sarcoidosis causes arterial and venous infarcts or tran-
sient ischemic attacks [6, 16, 17]. 
  Granulomas in or adjacent to the brain parenchyma may 
mimic gliomas or meningiomas [18]. Some can also cause 
cerebellopontine angle masses mimicking schwannomas. 
Masses may be asymptomatic, but they can obstruct the ven-
tricular system and cause hydrocephalus. Others may cause 
seizures [15]. 
Seizures 
  Seizures occur in 7-22% of patients with neurosarcoido-
sis (Table 1). They are the presenting manifestation in about 
10%, and may be generalized or focal [19]. Their etiologies 
include leptomeningeal infiltration with cortical irritation, 
parenchymal masses, metabolic disturbances related to hypo-
thalamic dysfunction, and possibly small vessel vasculitis 
associated with granulomatous angiitis. Cerebrospinal fluid 
Table 1.  Neurologic Manifestations of Sarcoidosis 
  Zajicek  
et al. [20] 
N=68 
Joseph and 
Scolding [9] 
N=30 
Pawate  
et al. [11] 
N=54 
Delaney, 
et al. [5] 
N = 23 
Stern, 
et al. [4] 
N = 33 
Chapelon, 
et al. [6] 
N = 35 
Oksanen  
[10] 
N = 50 
Lower, 
et al. [3] 
N = 71 
Wiederholt, 
Siekert [7] 
N = 28 
Cranial neuropathy % (N)  34 (23)  28 (8)  23 (12)  48 (11)  73 (24)  34 (12)  42 (21)  70 (50)  64 (18) 
Optic neuropathy  38 (26)  37 (11)  35 (19)  30 (7)  12 (4)  3 (1)  10 (5)  10 (7)  21 (6) 
Endocrine/hypothalamic dysfunction  3 (2)  17 (5)  2 (1)  26 (6)  15 (5)  11 (4)  10 (5)  8 (6)  25 (7) 
Other intracranial mass  --  --  --  35 (8)  0 (0)  --       
Seizures  --  10 (3)  17 (9)  22 (5)  0 (0)  14 (5)  18 (9)  7 (5)  18 (5) 
Meningitis  12 (8)  22 (7)  --  26 (6)  18 (6)  40 (14)  8 (4)  40 (28)  -- 
Myelopathy  28 (19)  15 (5)  19 (10)  9 (2)  6 (2)  0 (0)  10 (5)  --  4 (1) 
Peripheral Neuropathy  --  --  2 (1)  4 (1)  6 (2)  40 (14)  18 (9)  4 (3)  14 (4) 
Myopathy  --  --  --  9 (2)  12 (4)  26 (6)  10 (5)  --  7 (2) Neurosarcoidosis  Current Neuropharmacology, 2011, Vol. 9, No. 3    431 
and electroencephalography results may correlate poorly 
with clinical findings [5]. The overall prognosis can be poor 
because of the severity of CNS disease [5]. The seizures are 
usually well-controlled with anticonvulsants [19]. 
SPINAL CORD AND ITS COVERINGS 
  Neurosarcoidosis can cause arachnoiditis, cauda equina 
dysfunction, extra- and intra-dural, extra-medullary and in-
tra-medullary lesions. The incidence in modern studies util-
izing MRI is 15-28% [9, 11, 20]. Junger, et al., reported 16 
patients with intra-medullary lesions studied retrospectively. 
MRI and clinical findings were noted. Five patients had sar-
coidosis isolated to the spinal cord, while ten had systemic 
disease. The median age of onset was 35. Patients had mye-
loradicular symptoms. MRI showed spinal cord enlargement 
in seven patients, atrophy in four, and focal regions of in-
creased T2 signal in two. One patient had diffusely increased 
T2 signal throughout the spinal cord. There was multifocal 
or focal enhancement in 50% and diffuse enhancement in 1 
of 12 [21]. 
PERIPHERAL NEUROPATHY 
  Peripheral neuropathy occurs in 4-20% of patients with 
neurosarcoidosis (Table 1). Subtypes include chronic sen-
sorimotor axonal polyneuropathy, multiple mononeuro-
pathies, sensory polyneuropathy including small-fiber neu-
ropathy, acute inflammatory demyelinating polyneuropathy 
(AIDP) and chronic inflammatory demyelinating polyneuro-
pathies [22-26]. The overall incidence of neuropathy in Ok-
sanen’s series was relatively high at 40% due to a relatively 
large number of mononeuropathies. The ulnar and peroneal 
nerves were most commonly affected [10]. Neuropathy   
can occur at various stages of sarcoidosis, and it can be the 
initial feature. Cranial neuropathies are more commonly   
encountered with the AIDP and multifocal mononeuropathy 
forms. 
  The presentation depends on the type of neuropathy. Di-
agnosis is typically confirmed by nerve biopsy, which shows 
the characteristic noncaseating granulomas, (Fig. 1). In some 
biopsy specimens, there is also evidence of necrotizing vas-
culitis or microvasculitis [24]. The mechanism of the neu-
ropathy is often uncertain but could be due to compression 
by granulomas and immune factors with either axonal loss or 
demyelination. Vasculitis can also cause ischemic axon loss. 
Electrodiagnostic studies in patients with an AIDP presenta-
tion are similar to those seen in Guillain-Barré syndrome. 
CSF pleocytosis is more likely to be present in the patients 
with sarcoidosis rather than in typical AIDP, though a pleo-
cytosis with an elevated CSF protein can also be present in 
HIV-associated AIDP for example [27]. A low CSF glucose 
would favor sarcoidosis. 
  Evaluation of intraepidermal nerve fiber density may be 
useful in confirming a diagnosis of small-fiber neuropathy 
when suspected and when electrodiagnostic studies do not 
show large-fiber neuropathic dysfunction. Subclinical in-
volvement may also be identified by either test [28]. 
MYOPATHY 
  Muscle involvement is commonly noted in autopsy and 
clinical series, and it is usually asymptomatic [29, 30]. It 
may be detected subclinically in up to 50% of sarcoidosis 
patients who undergo muscle biopsy as part of the evaluation 
[29]. Symptomatic muscle involvement is present in less 
than 1% of patients with systemic sarcoidosis. It is somewhat 
more common in conjunction with other features of neuro-
sarcoidosis (Table 1), in post-menopausal women, [31] and 
in the presence of erythema nodosum [29]. Its onset tends to 
occur later with other organ involvement [31]. Presentations 
include acute myopathy with a polymyositis-like presentation 
and chronic myopathy with muscle wasting [30]. Patients 
may have muscle tenderness, and sometimes nodules may be 
palpated [32, 33]. Diaphragm involvement is rare [34]. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). A hematoxylin- and eosin-stained paraffin section of a 
superficial peroneal sensory nerve biopsy specimen reveals a granu-
loma consisting of epithelioid histiocytes surrounded by a rim of 
lymphocytes. Giant cells are not seen and may not be readily appar-
ent in most nerve granulomas. The granuloma is in the epineurium 
adjacent to the endoneurium (E). 
  The serum creatine kinase is sometimes elevated. EMG 
reveals “myopathic” motor unit potentials with or without 
fibrillation potentials [35]. Diagnosis is confirmed by identi-
fication by noncaseating granulomas in muscle tissue. They 
are usually located in the perimysium, and sometimes occur 
in the endomysium but do not typically infiltrate myofibers 
distant to the granuloma (Fig. 2). 
DIAGNOSIS 
  The criteria for diagnosis of neurosarcoidosis usually 
include a compatible clinical scenario, histologic identifica-
tion of a noncaseating granuloma in any tissue, and imaging 
or laboratory tests supportive of the diagnosis. Zajicek et al. 
proposed diagnostic criteria with levels of certainty, and 
these criteria are now commonly used [20]. All categories 
include a clinical presentation suggestive of neurosarcoidosis 
and exclusion of other diagnoses. These are the criteria for 
possible neurosarcoidosis. For a definite  diagnosis, there 
should also be “positive” nervous system histology. For a 
diagnosis of probable neurosarcoidosis, laboratory support 
(CSF or MRI) is required as well as evidence of systemic 
sarcoidosis (histological, Kveim test, and/or two or more 
indirect indicators: suggestive Gallium scan, chest imaging, 
or serum ACE) [20]. 432    Current Neuropharmacology, 2011, Vol. 9, No. 3  David Lacomis 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). A photomicrograph of a hematoxylin- and eosin-stained 
paraffin section from a skeletal muscle biopsy specimen reveals a 
granuloma containing giant cells. It is located in the perimysium. 
Some lymphocytes course outside the granuloma, but the adjacent 
muscle fibers are mostly unaffected. 
  The approach to diagnosis is dependent on the presumed 
localization of the neurologic lesion and whether or not the 
patient has known evidence of systemic sarcoidosis [2]. 
Since intrathoracic disease is most common, screening for 
systemic sarcoidosis usually starts with a chest x-ray. Chest 
x-rays are abnormal in up to 90% of sarcoidosis patients, and 
hilar adenopathy is the most common finding. High resolu-
tion chest CT is more sensitive, especially for detecting nod-
ules along the bronchovascular bundle and subpleural re-
gions [36]. In addition, skin lesions should be sought. The 
presence of Löfgren syndrome (erythema nodosum, bilateral 
hilar adenopathy, fever and arthritis) is practically diagnostic 
of sarcoidosis. Ophthalmologic evaluation, including slit 
lamp exam for uveitis and other ocular findings, should also 
be performed. An endocrine evaluation should be undertaken 
if hypothalamic or pituitary dysfunction is suspected. 
  A minority of patients may have an elevated erythrocyte 
sedimentation rate. Elevations in serum alkaline phosphatase 
and calcium are uncommon. The serum angiotensin convert-
ing enzyme (ACE) level may be elevated in up to 65% of 
patients, usually in the setting of active disease, but it is in-
sensitive [6]. The Kveim test, which utilizes intradermal in-
jection of a single antigen from a spleen removed in 1981, is 
very sensitive [20], but it is not readily available. 
  Bronchoalveolar lavage may reveal a lymphocytosis with 
a high CD4:CD8 ratio, but this finding is also insensitive and 
non-specific [36]. Gallium-67 scanning is cumbersome and 
findings are nonspecific, but it may be useful in detecting a 
site for biopsy [6, 36]. Whole-body flourodeoxyglucose posi-
tron emission tomography may be more sensitive and useful 
in identifying occult granulomas, but a positive finding by 
itself is not diagnostic and such scanning is expensive and 
not widely available. Its utility has not been compared 
against Gallium-67 imaging [12]. 
  Ultimately, a tissue diagnosis is required in the vast ma-
jority of patients. Common methods of biopsy would include 
transbronchial or endobronchial biopsies, lymph node bi-
opsy, as well as biopsy of skin lesions [37]. Peripheral nerve, 
muscle, and sometimes CNS tissues are biopsied in patients 
with isolated neurosarcoidosis. Intraepidermal nerve fiber 
density analysis with punch skin biopsy may reveal reduced 
density scores [28], consistent with a small fiber neuropathy. 
Non-caseating granulomas are not expected on normal ap-
pearing skin of biopsy sites for nerve fiber density analysis. 
  In patients already diagnosed with sarcoidosis, additional 
recommended evaluations include pulmonary function test-
ing, complete blood count, serum chemistries with calcium, 
liver enzymes and renal function tests, urinalysis, an electro-
cardiogram, and tuberculin skin test [1, 36]. 
Neurosarcoidosis 
  Computed tomographic (CT) scans may show hydro-
cephalus, intracranial calcification, and enhancing nodules, 
[4] but they are less sensitive than MRI. MRI is very sensi-
tive in detecting abnormalities in neurosarcoidosis, [20, 38-
40] but it is nonspecific. It can detect evidence of meningeal 
inflammation, diencephalic involvement and parenchymal 
lesions in about 40%. Non-specific white matter changes are 
most common. In particular, periventricular T2-hyperintense 
lesions are often seen [11, 41, 42] and may mimic multiple 
sclerosis, also affecting the corpus callosum [43]. Optic 
nerve enlargement and enhancement also occurs in some 
[20]. In contrast to multiple sclerosis, linear enhancement 
along Virchow-Robin spaces may be more typical of neuro-
sarcoidosis and stem from granulomatous vasculitis; nonspe-
cific leptomeningeal and parenchymal enhancement occurred 
in 19% in one series [11]. In addition, parenchymal or men-
ingeal enhancement may last longer (more than a few weeks) 
with neurosarcoidosis than with multiple sclerosis [20]. 
  In patients with leptomeningeal involvement, the CSF 
findings are as follows: 40-70% exhibit pleocytosis; 40-73% 
has an elevated protein; and 10-20% has a low glucose [4, 5, 
20, 44]. The mean number of CSF lymphocytes reported in 
the patients with pleocytosis in one series was 78, with a 
range from 8-300 per mm
3 [5]. Oligoclonal bands and an 
elevated IgG index are encountered in up to 53% [20, 45]. 
The oligoclonal bands are usually accompanied by an eleva-
tion in protein [9]. Cultures for bacteria, fungi, and mycobac-
teria must be sterile, and cytology should be negative for 
neoplasm. CSF is often normal with isolated facial palsies 
[8]. From subsets of retrospectively studied patients, it has 
been found that CSF ACE levels are elevated in 24-55%, and 
thus insensitive, but they may be highly specific (94-95%) 
[46]. 
  Electroencephalography may reveal focal or generalized 
slowing, but it is usually normal unless patients are having 
seizures [4]. Electrodiagnostic testing may be useful in pa-
tients with suspected neuropathy or myopathy. 
PATHOGENESIS 
  The cause remains uncertain. Observations of outbreaks 
and clustering of disease suggests a common environmental 
exposure, infectious agent, or genetic predisposition in some 
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causative. However, familial clustering in 19% of affected 
African-American families and in 5% of Caucasian families 
as well as associations with class I HLA-A1 and -B8 and 
class II HLA-DR 3 in Caucasians [49, 50] and HLA-DRB1 
and DQB1 [2] suggest a genetic predisposition. There may 
also be a role for vitamin D deficiency, which is more preva-
lent in African-Americans [51]. 
  As mentioned, the histopathologic lesion is the non-
caseating granuloma. It is thought that granuloma formation 
begins with exposure to an antigen and is followed by T-cell 
and macrophage activation via a classic major histocompati-
bility complex (MHC) II-mediated pathway. It is further 
mediated by T-helper cells and activated T cells. Macro-
phages and dendritic cells release cytokines and chemokines, 
including interferon , tumor necrosis factor , and interleu-
kin (IL) including IL-2, IL-6, IL-12, IL-15, IL-16, and IL-18. 
Other cells are then recruited to the site of granuloma forma-
tion and become activated [51]. 
  Also in favor of a driving T-helper response, there is evi-
dence of decreased expression of natural killer cell inhibitory 
receptors on CD8+ T cells. This scenario possibly causes 
impairment in controlling the cell-mediated response [51]. 
Following accumulation of mononuclear inflammatory cells 
in the affected tissues, macrophages tightly aggregate and 
differentiate into epithelioid histiocytes and multinucleated 
giant cells. CD-4 and CD-8+ lymphocytes and some B cells 
form a rim around the granuloma. Subsequently, the inflam-
matory nodule becomes encased in fibroblasts, mast cells, 
collagen fibers, and proteoglycans, forming a destructive   
region of fibrosis through an incompletely understood process. 
TREATMENT 
Corticosteroids 
  In all forms of neurosarcoidosis, corticosteroids are typi-
cally the first line of treatment. There are no clinical trials 
that dictate specific doses or dosing schedules. Typically oral 
prednisone is dosed at 40-80 mg per day. In more severe 
CNS disease, intravenous corticosteroids may be adminis-
tered. Benefits vary from substantial improvement – about 
half – to no benefit [5], and some patients succumb despite 
treatment [10]. Results of corticosteroid therapy from large 
series are summarized below. 
  In the study by Lower, et al., 61 patients with neurosar-
coidosis received corticosteroids. Those with isolated facial 
nerve palsies had an excellent response. Forty-eight others 
were treated with corticosteroids alone. Four died, but one 
death was unrelated to neurosarcoidosis. Thirty went on to 
have subsequent therapies and fourteen (29%) were treated 
long-term with prednisone only [3]. Chapelon, et al., treated 
31 patients with corticosteroids [6]. Ten patients completely 
recovered. Three required subsequent therapies with chlo-
rambucil, methotrexate, or cyclosporine, and recovered fully. 
Ten patients treated with corticosteroids alone improved but 
had persistent deficits. 
  Of the 28 patients with neurosarcoidosis reported by 
Wiederholt,  et al., corticosteroids were used in nine. One 
died; four improved or recovered; and four were unchanged. 
Of note, 14 patients were not treated with immunosuppres-
sive agents, and two received only anticonvulsants. Of these, 
at least ten improved or recovered [7]. In the series of 33 
patients reported by Stern, et al., 25 were known to receive 
prednisone. Of these, there was improvement or resolution in 
at least 19. One died. The response was unknown in several, 
and there was no improvement in at least one other. Some of 
the patients who benefited also had persistent deficits [4]. 
 Zajicek  et al. reported 48 patients treated for at least 18 
months. Thirty-four received oral corticosteroids with or 
without IV methylprednisolone boluses. Twenty-nine per-
cent improved or stabilized, while 71% worsened and then 
received other immunotherapy or cranial irradiation [20]. 
Joseph  et al. treated 30 patients in a similar fashion with 
similar outcomes [9]. 
 Pawate  et al. treated 38 patients with either oral or IV 
corticosteroids followed by maintenance oral steroids. 
Eleven received corticosteroids alone, and the rest were of-
fered other immunotherapies. In general, patients with bilat-
eral optic neuropathies and those with widespread paren-
chymal or meningeal disease did poorly [11]. Scott et al. 
treated 19 patients with corticosteroids alone (60-80 
mg/day). Eight of 19 were successfully weaned off in 2-3 
years. Overall, 35% improved; 55% stabilized; and 10% 
worsened. Patients with more severe CNS involvement were 
treated with combination therapies (discussed in next sec-
tion) [52]. 
  The precise mechanisms of action of corticosteroids in 
treating neurosarcoidosis are not known, but presumably 
benefit is due to the known anti-inflammatory and immuno-
modulating effects. These include interference with the func-
tion of leukocytes and fibroblasts, inhibiting access of leuko-
cytes to inflammatory sites, and suppressing the myriad of 
humoral factors such as cytokine release involved in granu-
loma formation [53]. In particular, glucocorticoids antago-
nize the differentiation of macrophages and inhibit their 
functions. They block the release of cytokines such as IL-1, 
IL-6, and tumor necrosis factor  [53]. Corticosteroids also 
inhibit T cell activation by binding to T cell receptors. In 
contrast, the immunosuppressive effects of corticosteroids 
affect B cells less, though they do reduce serum immuno-
globulin levels, at least transiently. 
  Patients who are treated with corticosteroids should re-
ceive appropriate prophylaxis for osteoporosis and be moni-
tored for hyperglycemia, cataract formation, psychiatric and 
infectious complications. They should eventually be treated 
with the lowest dose required to maintain benefit. Morning 
dosing should be used. Patients also need to be aware of the 
risk of developing cosmetic changes. Adrenal insufficiency 
may occur, especially if the dose is rapidly tapered or 
abruptly discontinued. Patients may also be at increased risk 
for peptic ulcer diseases, especially if they receive concomi-
tant non-steroidal anti-inflammatory drugs [53]. 
SECOND LINE TREATMENT OPTIONS 
“Steroid-sparing” Immunosuppressive Drugs 
  Second-line treatments may include methotrexate, cy-
closporine, azathioprine, cyclophosphamide, chlorambucil, 
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patients with cyclosporine in a 12-month open label trial. 
They were able to lower baseline corticosteroid doses by 30-
58%. It appeared that cyclosporine was beneficial in some 
patients, but others worsened despite a combination of cy-
closporine and corticosteroid therapy [54]. Cyclosporine 
inhibits the CD4 cell immune response and IL-2 release. It 
can be started at 4 mg/kg/day in divided doses and requires 
careful monitoring of trough levels and for adverse events 
including hypertension, renal failure, hypomagnesemia, and 
neurotoxicity. 
  In the series by Lower, et al., methotrexate, a dihydrofo-
late reductase inhibiter, successfully treated 61% (17 of 28) 
at doses of 5-15 mg/week. Liver biopsies, performed in 13 
patients, did not reveal hepatotoxic changes. One patient 
developed neutropenia, and one had refractory nausea. Pa-
tients treated with methotrexate also require monitoring for 
pulmonary and renal toxicity [3]. Administration of folinic 
acid may reduce toxicity. Intermittent IV cyclophosphamide 
(starting at 500-700 mg every two weeks) “controlled the 
disease” in 9 of 10 treated patients, and it was well-tolerated. 
Most were treated for six or more months and had been pre-
viously treated with prednisone and methotrexate. Some re-
mained on low-dose prednisone [3]. Cyclophosphamide is a 
potent immunosuppressant alkylating agent that cross-links 
DNA and RNA inhibiting protein synthesis. It requires care-
ful monitoring for infection, hemorrhagic cystitis, as well as 
bone marrow and other toxicities. 
 Agbogu,  et al., reported their retrospective experience 
with various medications for corticosteroid-refractory neuro-
sarcoidosis. Treatments included azathioprine (50-200 mg/day 
in 12 patients), cyclosporine (50-980 mg/day in 15 patients), 
cyclophosphamide (200 mg/day in three patients), chloram-
bucil (8-16 mg/day in two patients), and methotrexate (10-20 
mg/week in two patients). Of 26 patients, six (23%) had im-
provement while receiving alternative medications, and 35% 
were stabilized. Fifteen percent did not respond to alternative 
therapies. Some patients took different drugs alone or in 
combination. Specific treatment recommendations cannot be 
made based on this study, but the authors did conclude that 
the choice of alternative therapy should be determined “in 
part, by its potential adverse effects” [55]. In the study, two 
patients treated with azathioprine developed neutropenia and 
one developed abnormal liver function tests. None had pan-
creatitis. Allergic reactions, which occur in 10% of patients 
treated with azathioprine, were not reported. One developed 
neutropenia with cyclophosphamide. Two developed renal 
dysfunction on cyclosporine. The only patient treated with 
chlorambucil developed leukopenia. 
 Scott  et al. treated 26 patients with perceived severe CNS 
involvement with corticosteroids and steroid-sparing agents 
including methotrexate (n=18, 7.5-15 mg weekly), azathio-
prine (n=9, 150-200 mg daily), or monthly cyclophos-
phamide (n=9, 600-800 mg/m
2 for 3-6 months). Overall, 18 
(69%) improved; 4 (15%) stabilized; and 4 (15%) worsened 
including two deaths in patients with chronic meningitis 
[52]. 
  Sharma performed a retrospective study in 12 patients 
with neurosarcoidosis treated with chloroquine or hydroxy-
chloroquine for 6 to 21 months. These antimalarial drugs are 
used for treatment of connective tissue diseases and have an 
uncertain mechanism of action in sarcoidosis. Hydroxy-
chloroquine prevents insulin degradation in the liver and 
suppresses gluconeogenesis, increasing peripheral utilization 
of glucose; so, it is particularly attractive to use in patients 
also treated with corticosteroids. Sharma reported that 10 of 
12 patients had either stabilization or improvement in neu-
rologic symptoms. These patients had previously failed to 
respond to corticosteroids or developed corticosteroid side-
effects [56]. Patients must be monitored for ocular toxicity, 
but such effects were not observed. 
Biological Agents 
  Based on the presence of increased cytokine activity in 
the inflammatory response, especially increased levels of 
tumor necrosis factor (TNF), treatment with TNF  blockers 
has been utilized. Eighteen patients with ocular sarcoidosis 
were treated with either etanercept or placebo in a double-
blind, randomized trial. No benefit was seen in this small 
study, and there were no severe adverse events [57]. 
  In contrast, the results of an open label study using in-
fliximab and mycophenolate mofetil were promising but not 
definitive. Patients with CNS sarcoidosis who had “failed” 
treatment with steroids were given infliximab, and six of 
seven were also treated with mycophenolate mofetil. There 
was no placebo group. All patients reported significant bene-
fit, both symptomatically and with regard to reversal of neu-
rological deficits or control of seizure activity. There was 
also universal benefit as detected by MRI lesion size or 
gadolinium enhancement. There were no serious adverse 
events. The TNF  neutralizer was coupled with mycophe-
nolate, based on standard practice which postulates that the 
combination of infliximab with an oral immunosuppressive 
agent prevents otherwise expected development of human 
anti-chimeric antibodies [58]. Hopefully, this treatment com- 
bination will be subjected to a controlled prospective study. 
  Infliximab treatment was also associated with improve-
ment in small-fiber neuropathy with autonomic involvement 
in one patient [59]. Intravenous immunoglobulin was also 
thought to be beneficial in a single patient with sensorimotor 
axonal polyneuropathy from sarcoidosis [60]. 
Cranial Irradiation 
  There have been a few anecdotal reports of benefit from 
cranial irradiation [40]. Of the two patients reported by 
Chapelon,  et al., one had chronic meningitis, psychiatric 
disturbances and seizures [6]. He was unresponsive to corti-
costeroids and methotrexate, but recovered after 200 rads. 
The other had hemiparesis, an extrapyramidal syndrome, and 
severe psychiatric features unresponsive to steroids, but im-
proved dramatically after 6000 rads. There was also dramatic 
improvement in CT scan findings [6]. Radiotherapy (1.3-3.6 
Gy/day for 3-24 weeks) was also said to be beneficial in one 
of three patients treated by Agbogu, et al. [55]. 
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